Biomarker and health marker study in myotonic dystrophy type 1
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study measures physical and lab “health markers” in people with myotonic dystrophy type 1 (DM1) to better understand how the disease changes over time. Some participants may also have a muscle biopsy to study tissue differences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old
- You have a confirmed DM1 diagnosis (by genetic test or clinical research criteria)
- You can give informed consent (and you’re able to follow study instructions)
- You do not have major uncontrolled kidney/liver problems, uncontrolled diabetes, or uncontrolled thyroid problems
- You are not currently using alcohol or other substances in an uncontrolled way
- You are not already enrolled in another DM1 trial (and haven’t been in one in the last 6 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ATX-01 for people with myotonic dystrophy type 1 (DM1), a condition that causes muscle weakness and stiffness. The study aims to see if ATX-01 can help reduce symptoms like muscle stiffness (myotonia) and improve daily function.
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
This study is a long-term follow-up for people with myotonic dystrophy type 1. It aims to find better ways to measure how the disease progresses, which could help develop future treatments.
This study follows people with myotonic dystrophy type 1 (DM1) over time to learn more about how the disease progresses. It collects health information and samples to help improve care.
This study is following people with myotonic dystrophy over 24 months to better understand the disease by combining past medical records already in a registry with new check-ups. It doesn't test a new treatment but helps researchers learn about the condition, which may lead to better care in the future.
This study tests whether remote assessments can track myotonic dystrophy type 1 (DM1) and looks at genetic factors. It aims to find better ways to monitor the disease from home.
Hear when a new Myotonic Dystrophy 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.